Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On August 11, 2025, Edesa Biotech, Inc. (EDSA) announced financial results for the third quarter of fiscal year 2025 that ended June 30, 2025 and provided a business update.</li><li>During the quarter, the company advanced manufacturing activities to support U.S. regulatory approval for a Phase 2 study of EB06 in the treatment of vitiligo.</li><li>Based on current availability of manufacturing slots at third-party vendors, we estimate that drug manufacturing data for EB06 is likely to be submitted to the U.S. Food and Drug Administration (FDA) before the end of calendar 2025.</li></ul>

On August 11, 2025, Edesa Biotech, Inc. (EDSA) announced financial results for the third quarter of fiscal year 2025 that ended June 30, 2025 and provided a business update.During the quarter, the company advanced manufacturing activities to support U.S. regulatory approval for a Phase 2 study of EB06 in the treatment of vitiligo.Based on current availability of manufacturing slots at third-party vendors, we estimate that drug manufacturing data for EB06 is likely to be submitted to the U.S. Food and Drug Administration (FDA) before the end of calendar 2025.

EDSA: EB06 Manufacturing to be Completed by End of 2025 